Successful cancer treatments can inadvertently trigger secondary malignancies years later
Effective cancer treatments can cause secondary malignancies years later by inducing genomic instability in surviving stem cells, a phenomenon increasingly documented in long-term survivors within aging populations like Japan's.
Therapy-related acute myeloid leukemia (tAML) represents a profound biological tradeoff where the very interventions that eliminate primary tumors induce lethal mutations in healthy tissue. A population-based study in Japan has documented a rising incidence of these secondary malignancies, driven by the delayed effects of chemotherapy and radiation on hematopoietic stem cells. These treatments damage DNA to trigger cell death, but surviving cells often harbor long-term genomic instability that can manifest as leukemia years after a patient achieves remission.